whether angiotensin receptor blockers increase cancer or cardiovascular risk

See updated FDA information regarding ARBs/cancer and Olmesartan/CV risks

There's controversy about whether angiotensin receptor blockers increase cancer or cardiovascular risk.

ARBs and cancer. A recent meta-analysis started a buzz that ARBs might lead to a small increased cancer risk...about 1 more case for every 143 patients using an ARB instead of placebo for 4 years.

One theory is that angiotensin might be involved in cell growth. ARBs increase free angiotensin by blocking its receptors.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote